Literature DB >> 7107838

Clostridium difficile and its cytotoxin in feces of patients with antimicrobial agent-associated diarrhea and miscellaneous conditions.

W L George, R D Rolfe, S M Finegold.   

Abstract

Fecal specimens from 223 subjects were evaluated for the presence of Clostridium difficile by use of a selective medium developed in our laboratory and for the presence of C. difficile cytotoxin. C. difficile and cytotoxin were detected in 89 and 83%, respectively, of patients with antimicrobial agent-associated pseudomembranous colitis (PMC). In patients in whom PMC was not documented, C. difficile and cytotoxin were present in only 37 and 21%, respectively. C. difficile and cytotoxin were also recovered from the feces of 6 and 3, respectively, of 13 antimicrobial recipients who did not have diarrhea. Although C. difficile appears to be a major cause of PMC, it is not responsible for at least some two-thirds of cases of antimicrobial agent-associated diarrhea in which PMC is not documented. Neither the recovery of C. difficile nor the detection of its cytotoxin should be considered diagnostic for C. difficile-induced disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7107838      PMCID: PMC272251          DOI: 10.1128/jcm.15.6.1049-1053.1982

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis.

Authors:  J G Bartlett; F J Tedesco; S Shull; B Lowe; T Chang
Journal:  Gastroenterology       Date:  1980-03       Impact factor: 22.682

2.  Identification of Clostridium difficile as a cause of pseudomembranous colitis.

Authors:  R H George; J M Symonds; F Dimock; J D Brown; Y Arabi; N Shinagawa; M R Keighley; J Alexander-Williams; D W Burdon
Journal:  Br Med J       Date:  1978-03-18

3.  Clinical and laboratory observations in Clostridium difficile colitis.

Authors:  J G Bartlett; N S Taylor; T Chang; J Dzink
Journal:  Am J Clin Nutr       Date:  1980-11       Impact factor: 7.045

4.  Treatment and prevention of antimicrobial agent-induced colitis and diarrhae.

Authors:  W L George; R D Rolfe; S M Finegold
Journal:  Gastroenterology       Date:  1980-08       Impact factor: 22.682

5.  Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters.

Authors:  J G Bartlett; A B Onderdonk; R L Cisneros; D L Kasper
Journal:  J Infect Dis       Date:  1977-11       Impact factor: 5.226

6.  Antibiotic-associated colitis: effects of antibiotics on Clostridium difficile and the disease in hamsters.

Authors:  R Fekety; J Silva; R Toshniwal; M Allo; J Armstrong; R Browne; J Ebright; G Rifkin
Journal:  Rev Infect Dis       Date:  1979 Mar-Apr

7.  Colitis induced by Clostridium difficile.

Authors:  J G Bartlett; T Chang; N S Taylor; A B Onderdonk
Journal:  Rev Infect Dis       Date:  1979 Mar-Apr

8.  Selective and differential medium for isolation of Clostridium difficile.

Authors:  W L George; V L Sutter; D Citron; S M Finegold
Journal:  J Clin Microbiol       Date:  1979-02       Impact factor: 5.948

9.  Aetiology of antimicrobial-agent-associated colitis.

Authors:  W L George; V L Sutter; E J Goldstein; S L Ludwig; S M Finegold
Journal:  Lancet       Date:  1978-04-15       Impact factor: 79.321

10.  Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations.

Authors:  R Viscidi; S Willey; J G Bartlett
Journal:  Gastroenterology       Date:  1981-07       Impact factor: 22.682

View more
  45 in total

1.  Asymptomatic carriage of Clostridium difficile in patients with cystic fibrosis.

Authors:  S L Peach; S P Borriello; H Gaya; F E Barclay; A R Welch
Journal:  J Clin Pathol       Date:  1986-09       Impact factor: 3.411

2.  Comparison of four laboratory tests for diagnosis of Clostridium difficile-associated diarrhea.

Authors:  J Jacobs; B Rudensky; J Dresner; A Berman; M Sonnenblick; Y van Dijk; A M Yinnon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-07       Impact factor: 3.267

Review 3.  The detrimental impact of extracellular bacterial proteases on wound healing.

Authors:  Sharon Lindsay; Angela Oates; Katie Bourdillon
Journal:  Int Wound J       Date:  2017-07-25       Impact factor: 3.315

4.  Prevalence of Clostridium difficile isolated from various raw meats in Korea.

Authors:  Joo Young Lee; Da Yeon Lee; Yong Sun Cho
Journal:  Food Sci Biotechnol       Date:  2018-01-24       Impact factor: 2.391

Review 5.  Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance.

Authors:  Kathleen Mullane
Journal:  Ther Adv Chronic Dis       Date:  2014-03       Impact factor: 5.091

6.  Prairie dog model for antimicrobial agent-induced Clostridium difficile diarrhea.

Authors:  E L Muller; H A Pitt; W L George
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

7.  Six rapid tests for direct detection of Clostridium difficile and its toxins in fecal samples compared with the fibroblast cytotoxicity assay.

Authors:  David K Turgeon; Thomas J Novicki; John Quick; LaDonna Carlson; Pat Miller; Bruce Ulness; Anne Cent; Rhoda Ashley; Ann Larson; Marie Coyle; Ajit P Limaye; Brad T Cookson; Thomas R Fritsche
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

8.  Commercial latex agglutination test for detection of Clostridium difficile-associated diarrhea.

Authors:  M T Kelly; S G Champagne; C H Sherlock; M A Noble; H J Freeman; J A Smith
Journal:  J Clin Microbiol       Date:  1987-07       Impact factor: 5.948

9.  Improvement of Clostridium difficile isolation by heat-shock and typing of the isolated strains by SDS-PAGE.

Authors:  M Lahn; G Tyler; W Däubener; U Hadding
Journal:  Eur J Epidemiol       Date:  1993-05       Impact factor: 8.082

10.  Evaluation of the usefulness of counterimmunoelectrophoresis for diagnosis of Clostridium difficile-associated colitis in clinical specimens.

Authors:  T C Wu; J C Fung
Journal:  J Clin Microbiol       Date:  1983-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.